PicoCELA (NASDAQ:PCLA) Issues Earnings Results

PicoCELA (NASDAQ:PCLA) announced its quarterly earnings results on Friday. The company reported ($3.30) EPS for the quarter, FiscalAI reports. The firm had revenue of $1.16 million during the quarter.

PicoCELA Trading Down 1.3%

Shares of PicoCELA stock opened at $6.95 on Friday. PicoCELA has a 1 year low of $1.35 and a 1 year high of $19.61. The company has a 50 day simple moving average of $6.46 and a two-hundred day simple moving average of $4.68.

Wall Street Analyst Weigh In

A number of brokerages have commented on PCLA. Wall Street Zen raised shares of PicoCELA to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.